All Stories

  1. Elevated Troponins after COVID-19 Hospitalization and Long-Term COVID-19 Symptoms: Incidence, Prognosis, and Clinical Outcomes—Results from a Multi-Center International Prospective Registry (HOPE-2)
  2. Reducing bleeding risk in patients on oral anticoagulation therapy
  3. Peripheral artery disease: Update on etiology, pathophysiology, diagnosis and treatment
  4. Predicting Bleeding in Cancer-Associated Venous Thromboembolism: Another Milestone Achieved
  5. Reticulated Platelets: A Promising Prognosis Marker in Cardiovascular Diseases
  6. Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment
  7. Prospective observational registry of perioperative and periprocedural management of antithrombotic therapy in “real world”: the REQXAA study
  8. Impact of particulate matter on the incidence of atrial fibrillation and the risk of adverse clinical outcomes: A review
  9. Impact of renal function on Ticagrelor-induced antiplatelet effects in coronary artery disease patients
  10. Post-COVID-19 syndrome and diabetes mellitus: a propensity-matched analysis of the International HOPE-II COVID-19 Registry
  11. Simplified Geleijnse score for identifying chest pain features associated with coronary ischemia
  12. Molecular mechanisms of postoperative atrial fibrillation in patients with obstructive sleep apnea
  13. Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis
  14. Imaging in atrial fibrillation: A way to assess atrial fibrosis and remodeling to assist decision-making
  15. Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban
  16. Polypharmacy and adverse events in atrial fibrillation: Main cause or reflection of multimorbidity?
  17. Ibrutinib use and adverse cardiovascular outcomes: A United States federated electronic medical records analysis
  18. Factors Associated with Progression of Atrial Fibrillation and Impact on All-Cause Mortality in a Cohort of European Patients
  19. Post-COVID-19 Symptoms and Heart Disease: Incidence, Prognostic Factors, Outcomes and Vaccination: Results from a Multi-Center International Prospective Registry (HOPE 2)
  20. Thoracic aortic aneurysm and atrial fibrillation: clinical associations with the risk of stroke from a global federated health network analysis
  21. Impact of ABC (Atrial Fibrillation Better Care) pathway adherence in high-risk subgroups with atrial fibrillation: A report from the ESC-EHRA EORP-AF long-term general registry
  22. Patient selection, peri-procedural management, and ablation techniques for catheter ablation of atrial fibrillation: an EHRA survey
  23. Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study
  24. Contemporary management of atrial fibrillation and the predicted vs. absolute risk of ischaemic stroke despite treatment: a report from ESC-EHRA EORP-AF Long-Term General Registry
  25. Adherence to the “Atrial fibrillation Better Care” (ABC) pathway in patients with atrial fibrillation and cancer: A report from the ESC-EHRA EURObservational Research Programme in atrial fibrillation (EORP-AF) General Long-Term Registry
  26. Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries
  27. Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry
  28. Editorial: New horizons in the management of patients with atrial fibrillation: Interactions with the gastrointestinal system
  29. Polypill Strategy in Secondary Cardiovascular Prevention
  30. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry
  31. Predicting heart failure in atrial fibrillation patients: What about using biomarkers?
  32. A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry
  33. Epidemiology and impact of frailty in patients with atrial fibrillation in Europe
  34. Gender differences in antithrombotic treatment in patients with atrial fibrillation from Spain versus the rest of Western Europe. GLORIA-AF Program
  35. MiR-146a Contributes to Thromboinflammation and Recurrence in Young Patients with Acute Myocardial Infarction
  36. Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper
  37. Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVID‐19: A Propensity Score‐Matched Cohort Analysis of the HOPE‐COVID‐19 Registry
  38. Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study
  39. Impact of anthropometric factors on outcomes in atrial fibrillation patients: analysis on 10 220 patients from the European Society of Cardiology (ESC)-European Heart Rhythm Association (EHRA) EurObservational Research Programme on Atrial Fibrillation ...
  40. Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: the ESC-EORP CICD-LT registry
  41. Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry
  42. Impact of Integrated Care Management on Clinical Outcomes in Atrial Fibrillation Patients: A Report From the FANTASIIA Registry
  43. Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry
  44. Impact of diabetes on the management and outcomes in atrial fibrillation: an analysis from the ESC-EHRA EORP-AF Long-Term General Registry
  45. Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study
  46. The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort
  47. Prediction of ischemic stroke in different populations: a comparison of absolute stroke risk and CHA2DS2-VASc in real-world and clinical trial patients
  48. Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC‐EHRA EURObservational research programme in atrial fibrillation general long‐term registry
  49. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascul...
  50. Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists
  51. Clinical implications of diabetes mellitus in patients with acute coronary syndrome: Prognostic role and use of new P2Y12 receptor inhibitors
  52. Impact of renal impairment on atrial fibrillation: ESC‐EHRA EORP‐AF Long‐Term General Registry
  53. Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation
  54. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR
  55. Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry
  56. Antithrombotic therapy and clinical outcomes at 1 year in the Spanish cohort of the EORP‐AF Long‐term General Registry
  57. Impact of sex differences and network systems on the in-hospital mortality of patients with ST-segment elevation acute myocardial infarction
  58. Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry
  59. Outcomes of digoxin vs. beta blocker in atrial fibrillation: report from ESC–EHRA EORP AF Long-Term General Registry
  60. Sepsis of Patients Infected by SARS-CoV-2: Real-World Experience From the International HOPE-COVID-19-Registry and Validation of HOPE Sepsis Score
  61. Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry
  62. Relationship between multimorbidity and outcomes in atrial fibrillation
  63. Prognosis Impact of Diabetes in Elderly Women and Men with Non-ST Elevation Acute Coronary Syndrome
  64. Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases
  65. Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes
  66. Comorbidity burden and revascularization benefit in elderly patients with acute coronary syndrome
  67. Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry
  68. COVID‐19 and the impact of arterial hypertension—An analysis of the international HOPE COVID‐19 Registry (Italy‐Spain‐Germany)
  69. Characterization of atrial fibrillation in real-world patients: testing the 4S-AF scheme in the Spanish and French cohorts of the EORP-AF Long-Term General Registry
  70. Prediction of Residual Stroke Risk in Anticoagulated Patients with Atrial Fibrillation: mCARS
  71. Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real‐world vs. clinical‐trial evidence
  72. In-hospital outcomes of mechanical complications in acute myocardial infarction: Analysis from a nationwide Spanish database
  73. Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation
  74. Fibrilación auricular en pacientes con COVID-19. Utilidad de la puntuación CHA2DS2-VASc: un análisis del registro internacional HOPE COVID-19
  75. Atrial fibrillation in patients with COVID-19. Usefulness of the CHA2DS2-VASc score: an analysis of the international HOPE COVID-19 registry
  76. Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national and multicentre SULTAN registry
  77. Comments on the 2020 ESC/EACTS guidelines for the management of atrial fibrillation
  78. Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study)
  79. Underlying heart diseases and acute COVID-19 outcomes
  80. Anticoagulation Therapy in Patients With Coronavirus Disease 2019: Results From a Multicenter International Prospective Registry (Health Outcome Predictive Evaluation for Corona Virus Disease 2019 [HOPE-COVID19])
  81. Baseline CHA 2 DS 2 ‐VASc score and prognosis in octogenarians with non‐ST segment elevation acute coronary syndrome
  82. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
  83. Sex bias in admission to tertiary‐care centres for acute myocardial infarction and cardiogenic shock
  84. COVID-19 anosmia and gustatory symptoms as a prognosis factor: a subanalysis of the HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry
  85. Impact of frailty and atrial fibrillation in elderly patients with acute coronary syndromes
  86. Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications
  87. COVID-19 anosmia and gustatory symptoms as a prognosis factor: a subanalysis of the HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry
  88. Novel insights in the relationship of gut microbiota and coronary artery diseases
  89. Sepsis of Patients Infected by SARS-CoV-2: Real-World Experience from the International HOPE-COVID-19-Registry and Validation of HOPE Sepsis Score
  90. Outcomes in VKA‐treated patients with atrial fibrillation and chronic kidney disease: Clinical trials vs ‘real‐world’
  91. The interpretation of CHA2DS2-VASc score components in clinical practice: a joint survey by the European Heart Rhythm Association (EHRA) Scientific Initiatives Committee, the EHRA Young Electrophysiologists, the Association of Cardiovascular Nursing an...
  92. Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores
  93. Factor XI, much more than an innocent observer
  94. Influence of the matrix type over the concentration of GDF-15
  95. Prognostic Impact of Hyponatremia and Hypernatremia in COVID-19 Pneumonia. A HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry Analysis
  96. Incidence and outcomes of hospital treated acute myocarditis from 2003 to 2015 in Spain
  97. Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation
  98. Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry
  99. Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID‐19
  100. Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: A report from the FANTASIIA registry
  101. Particulate Matter and Temperature: Increased Risk of Adverse Clinical Outcomes in Patients With Atrial Fibrillation
  102. Impacto del tratamiento antitrombótico y los síndromes geriátricos en octogenarios con fibrilación auricular y cardiopatía isquémica. Fibrilación Auricular y Cardiopatía Isquémica en Longevos (FACIL)
  103. Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry
  104. Utilizing biomarkers associated with cardiovascular events in atrial fibrillation: informing a precision medicine response
  105. Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology
  106. Recomendaciones sobre el tratamiento antitrombótico durante la pandemia COVID-19. Posicionamiento del Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Española de Cardiología
  107. Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial
  108. A nurse‐led atrial fibrillation clinic: Impact on anticoagulation therapy and clinical outcomes
  109. Influence of sex on long-term prognosis in patients with atrial fibrillation treated with oral anticoagulants. Results from the prospective, nationwide FANTASIIA study
  110. Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy
  111. Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry
  112. Relationship of adverse events to quality of anticoagulation control in atrial fibrillation patients with diabetes: real-world data from the FANTASIIA Registry
  113. Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project
  114. Comments on the 2019 ESC guidelines on chronic coronary syndromes
  115. Comments on the 2019 ESC guidelines on acute pulmonary embolism
  116. Comments on the 2019 ESC guidelines on supraventricular tachycardia
  117. FRAIL Scale also Predicts Long-Term Outcomes in Older Patients With Acute Coronary Syndromes
  118. Prognostic impact of inappropriate doses of direct oral anticoagulants in clinical practice
  119. Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a “Real-world” Nationwide Registry: Insights From the FANTASIIA Study
  120. Comments on the 2019 ESC guidelines on diabetes, prediabetes, and cardiovascular disease
  121. Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias
  122. Early Small Creatinine Shift Predicts Contrast-Induced Acute Kidney Injury and Persistent Renal Damage after Percutaneous Coronary Procedures
  123. One‐year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: Results from a prospective and multicentre ACHILLES registry
  124. Association of Body Mass Index With Clinical Outcomes in Patients With Atrial Fibrillation: A Report From the FANTASIIA Registry
  125. Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation
  126. ‘Real-world’ observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin Ame...
  127. Are There Gaps in the Evidence on the Treatment of Mild Hypertension in Patients With Low Cardiovascular Risk? Response
  128. Optimized scoring tool to quantify the functional performance during the sit-to-stand transition with a magneto-inertial measurement unit
  129. Diagnosis and management of left atrial appendage thrombus in patients with atrial fibrillation undergoing cardioversion or percutaneous left atrial procedures: results of the European Heart Rhythm Association survey
  130. The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal
  131. High-sensitivity microsatellite instability assessment for the detection of mismatch repair defects in normal tissue of biallelic germline mismatch repair mutation carriers
  132. Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations
  133. Reply to: Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials
  134. A colorimetric method for the determination of different functional flavonoids using 2,2'-azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) and peroxidase
  135. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
  136. Optimal marker set assessment for motion capture of 3D mimic facial movements
  137. Epidemiology of Cardiac Myxoma in a Spanish Population. A 30-year Surgical Series
  138. Antisynthetase Syndrome and Autoantibodies: A Literature Review and Report of 4 Cases
  139. Under-prescription of novel antiplatelet drugs in patients with acute coronary syndrome and previous cardiovascular disease
  140. Mid-upper arm circumference predicts death in adult patients admitted to a TB ward in the Philippines: A prospective cohort study
  141. Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores
  142. Performance of alternative measures to body mass index in the assessment of moderate and severe under-nutrition among acutely unwell patients hospitalized in a TB ward in the Philippines: A cross-sectional study
  143. Devices for mechanical circulatory support and strategies for their management in cardiogenic shock
  144. 'Palaeoshellomics’ reveals the use of freshwater mother-of-pearl in prehistory
  145. Mitral Regurgitation and Prognosis After Non‐ST‐Segment Elevation Myocardial Infarction in Very Old Patients
  146. International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
  147. Galectin-3 and β-trace protein concentrations are higher in clinically unaffected patients with Fabry disease
  148. Comorbidity assessment for mortality risk stratification in elderly patients with acute coronary syndrome
  149. Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey
  150. High and low on-treatment platelet reactivity to P2Y12 inhibitors in a contemporary cohort of acute coronary syndrome patients undergoing percutaneous coronary intervention
  151. Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome
  152. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis
  153. Comments on the 2018 ESC Guidelines for the Management of Cardiovascular Diseases During Pregnancy
  154. Comments on the 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension
  155. Invasive Versus Conservative Strategy in Frail Patients With NSTEMI: The MOSCA-FRAIL Clinical Trial Study Design
  156. Toward mechanistic models for genotype–phenotype correlations in phenylketonuria using protein stability calculations
  157. Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials
  158. Diabetes mellitus, frailty and prognosis in very elderly patients with acute coronary syndromes
  159. A voxel-based method for designing a numerical biomechanical model patient-specific with an anatomical functional approach adapted to additive manufacturing
  160. Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial
  161. Switching of Oral P2Y12 Inhibitor Treatment in Patients with Acute Coronary Syndrome: Prevalence, Predictors, and Prognosis
  162. OUP accepted manuscript
  163. Statin Treatment and Prognosis of Elderly Patients Discharged after Non-ST Segment Elevation Acute Coronary Syndrome
  164. Comments on the 2018 ESC Fourth Universal Definition of Myocardial Infarction
  165. Comments on the 2018 ESC/EACTS Guidelines for Myocardial Revascularization
  166. Bleeding Risk Prediction in Patients With Dual Antiplatelet Therapy Undergoing Coronary Artery Bypass Grafting Surgery Using a Rapid Point-of-Care Platelet Function Test
  167. Conservatively managed patients with non-ST-segment elevation acute coronary syndrome are undertreated with indicated medicines
  168. Study description and baseline characteristics of the population enrolled in a multinational, observational study of teriparatide in postmenopausal women with osteoporosis: the Asia and Latin America Fracture Observational Study (ALAFOS)
  169. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
  170. Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies
  171. Efficacy and safety of peri-procedural bridging therapy with low molecular weight heparin in atrial fibrillation patients under vitamin K antagonists
  172. A multi‐layered nerve guidance conduit design adapted to facilitate surgical implantation
  173. Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies
  174. Identification of Noise Covariance Matrices to Improve Orientation Estimation by Kalman Filter
  175. Comments on the 2018 ESC Guidelines for the Diagnosis and Management of Syncope
  176. Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS‐BLED and GARFIELD‐AF Bleeding Scores
  177. Chronic Kidney Disease and Third-Generation P2Y12 Inhibitors Use in Patients With Acute Coronary Syndrome: Impact on the Prognosis at 1 Year
  178. Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated “Real-World” in Patients With Atrial Fibrillation
  179. Biochemical characterization of the skeletal matrix of the massive coral, Porites australiensis – The saccharide moieties and their localization
  180. Teriparatide Treatment Increases Mineral Content and Volume in Cortical and Trabecular Bone of Iliac Crest: A Comparison of Infrared Imaging With X-Ray–Based Bone Assessment Techniques
  181. Inhibition of enzymes involved in collagen cross-linking reduces vascular smooth muscle cell calcification
  182. Oral anticoagulation and comorbidities; too many details for clinical practice?
  183. A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the “Real-World” vs Clinical Trials
  184. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the Eu...
  185. Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU
  186. Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: Biomarker substudy results from a prospective study with rivaroxaban (X-TRA)
  187. Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS)
  188. European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), C...
  189. Translating guidelines into practice for the management of atrial fibrillation: results of an European Heart Rhythm Association Survey
  190. Invasive strategy and frailty in very elderly patients with acute coronary syndromes
  191. Wnt Signaling Pathways Are Dysregulated in Rat Female Cerebellum Following Early Methyl Donor Deficiency
  192. Molecular modularity and asymmetry of the molluscan mantle revealed by a gene expression atlas
  193. Teriparatide vs risedronate for osteoporosis – Authors' reply
  194. Disparities in the Estimation of Glomerular Filtration Rate According to Cockcroft‐Gault, Modification of Diet in Renal Disease‐4, and Chronic Kidney Disease Epidemiology Collaboration Equations and Relation With Outcomes in Patients With Acute Coronar...
  195. Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation
  196. Optimizing Vitamin K Antagonist Treatment in Patients with Mechanical Heart Valve Prosthesis
  197. Plant Lineage-Specific Amplification of Transcription Factor Binding Motifs by Miniature Inverted-Repeat Transposable Elements (MITEs)
  198. An Easy Assessment of Frailty at Baseline Independently Predicts Prognosis in Very Elderly Patients With Acute Coronary Syndromes
  199. Design-validation of a hand exoskeleton using musculoskeletal modeling
  200. Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project
  201. European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS)
  202. Relation of quality of anticoagulation control with different management systems among patients with atrial fibrillation: Data from FANTASIIA Registry
  203. Modeling and simulation of different and representative engineering problems using Network Simulation Method
  204. Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in ‘real-world’ atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients
  205. Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA 2 DS 2 -VASc and HAS-BLED
  206. Intra-ventricular thrombus resolution after anticoagulation therapy with rivaroxaban in patient with poor anticoagulation quality
  207. Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality
  208. Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial
  209. The growth of interest for astronomical X-ray polarimetry
  210. Global Geriatric Assessment and In-Hospital Bleeding Risk in Elderly Patients with Acute Coronary Syndromes: Insights from the LONGEVO-SCA Registry
  211. Comments on the 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases
  212. Comments on the 2017 ESC/EACTS Guidelines for the Management of Valvular Heart Disease
  213. Imaging Correlations in Heterodyne Spectra for Quantum Displacement Sensing
  214. Polyphenolic Compounds, Antioxidant, and Cardioprotective Effects of Pomace Extracts from Fetească Neagră Cultivar
  215. A new twist on sea silk: the peculiar protein ultrastructure of fan shell and pearl oyster byssus
  216. Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients
  217. Comments on the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease
  218. Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy
  219. Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIIA Registry
  220. Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol
  221. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
  222. Temporal Changes in Platelet Response in Acute Coronary Syndrome Patients With Prasugrel and Clopidogrel After Stent Implantation
  223. Comments on the 2017 ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-segment Elevation
  224. Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation
  225. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry
  226. Occupational radiation exposure in the electrophysiology laboratory with a focus on personnel with reproductive potential and during pregnancy: A European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS)
  227. Effects of a trail mountain race on neuromuscular performance and hydration status in trained runners
  228. Quality of oral anticoagulation with vitamin K antagonists in ‘real-world’ patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry
  229. Estimation of the wrist joint center of rotation
  230. Motion analysis of snare drum in relation with the musician’s expertise
  231. Emotional concerns and coping strategies in Low Grade Glioma patients and reliability of their caregivers in reporting these concerns: Findings from a cross-sectional study
  232. Efficacy of non-vitamin-K antagonist oral anticoagulants for intracardiac thrombi resolution in nonvalvular atrial fibrillation
  233. Research update for articles published in EJCI in 2015
  234. Therapeutic management and one-year outcomes in elderly patients with acute coronary syndrome
  235. Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation
  236. Enhancing the ‘real world’ prediction of cardiovascular events and major bleeding with the CHA2DS2-VASc and HAS-BLED scores using multiple biomarkers
  237. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry
  238. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Worki...
  239. Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes
  240. Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation
  241. Device-detected subclinical atrial tachyarrhythmias: definition, implications and management—an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad ...
  242. The future of nutrition: Nutrigenomics and nutrigenetics in obesity and cardiovascular diseases
  243. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisio...
  244. Percutaneous cryoablation of symptomatic venous malformations as a second-line therapeutic option: a five-year single institution experience
  245. Long‐Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC‐Stroke and CHA 2 DS 2 ‐VASc Scores
  246. Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoameri...
  247. Hypertension and Cardiac Arrhythmias: Executive Summary of a Consensus Document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and...
  248. Anti-inflammatory effects of omega 3 and omega 6 polyunsaturated fatty acids in cardiovascular disease and metabolic syndrome
  249. Low body weight and clinical outcomes in acute coronary syndrome patients: results of the ACHILLES Registry
  250. Shell extracts of the edible mussel and oyster induce an enhancement of the catabolic pathway of human skin fibroblasts, in vitro
  251. Analysis of the sEMG/force relationship using HD-sEMG technique and data fusion: A simulation study
  252. Micronutrient supplementation in gastric bypass surgery: prospective study on inflammation and iron metabolism in premenopausal women
  253. Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice
  254. Applicability of the modified CHA 2 DS 2 -VASc score for stroke risk stratification in Caucasian atrial fibrillation patients
  255. The Changing Landscape for Stroke Prevention in AF
  256. Evaluation of HAS-BLED and ORBIT Bleeding Risk Scores in Nonvalvular Atrial Fibrillation Patients Receiving Oral Anticoagulants
  257. Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation?
  258. Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture: Final Results of a 78-Week Randomized Clinical Trial
  259. Galectin-3 as a marker of interstitial atrial remodelling involved in atrial fibrillation
  260. Search for an Ultralight Scalar Dark Matter Candidate with the AURIGA Detector
  261. Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endo...
  262. Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial
  263. Long-term bleeding risk prediction in ‘real world’ patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores
  264. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients
  265. Predicting bleeding risk after coronary surgery: Let’s focus on modifiable risk factors and simple, practical decision making
  266. Comments on the 2016 ESC Guidelines for the Management of Atrial Fibrillation
  267. Deep conservation of bivalve nacre proteins highlighted by shell matrix proteomics of the Unionoida Elliptio complanata and Villosa lienosa
  268. Deciphering acute coronary syndrome biomarkers: High-resolution proteomics in platelets, thrombi and microparticles
  269. Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation
  270. Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor
  271. Formation of localized sand patterns downstream from a vertical cylinder under steady flows: Experimental and theoretical study
  272. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society ...
  273. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society ...
  274. Teriparatide and Risedronate After Hip Fracture
  275. Is oral anticoagulation needed in patients with atrial fibrillation and stent implantation at low–moderate risk of stroke?
  276. Oral anticoagulation in octogenarians with atrial fibrillation
  277. Randomized comparison between the invasive and conservative strategies in comorbid elderly patients with non-ST elevation myocardial infarction
  278. Organic matrices in metazoan calcium carbonate skeletons: Composition, functions, evolution
  279. Expression patterns of Irx genes in the developing chick inner ear
  280. The wearable cardioverter-defibrillator: current technology and evolving indications
  281. Structural Heart Disease in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Prevalence and Clinical Profile in a Spanish Sample
  282. Sport, health and sudden death
  283. Classification of physical activities based on body-segments coordination
  284. Extraction of the Brachialis muscle activity using HD-sEMG technique and canonical correlation analysis
  285. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF)
  286. The HAS-BLED score predicts long-term major bleeding and death in anticoagulated non-valvular atrial fibrillation patients undergoing electrical cardioversion
  287. Cardiac Arrhythmias in Patients with Chronic Kidney Disease: Implications of Renal Failure for Antiarrhythmic Drug Therapy
  288. Strategies for prediction and early detection of atrial fibrillation: present and future
  289. Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold
  290. Comparison of Risk Prediction With the CKD-EPI and MDRD Equations in Non-ST-Segment Elevation Acute Coronary Syndrome
  291. On the Way to a Better Use of Anticoagulants in Nonvalvular Atrial Fibrillation. Proposed Amendment to the Therapeutic Positioning Report UT/V4/23122013
  292. Validation of a method for noninvasive prenatal testing for fetal aneuploidies risk and considerations for its introduction in the Public Health System
  293. Denoising of HD-sEMG signals using canonical correlation analysis
  294. The Shell of the Invasive Bivalve Species Dreissena polymorpha: Biochemical, Elemental and Textural Investigations
  295. Do physicians correctly calculate thromboembolic risk scores? A comparison of concordance between manual and computer‐based calculation of CHADS2 and CHA2DS2‐VASc scores
  296. miRNA-197 and miRNA-223 and cardiovascular death in coronary artery disease patients
  297. Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies
  298. Evidence From Pacing in Obstructive Hypertrophic Cardiomyopathy
  299. Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS)
  300. Testing Quantum Gravity Induced Nonlocality via Optomechanical Quantum Oscillators
  301. Dynamical Two-Mode Squeezing of Thermal Fluctuations in a Cavity Optomechanical System
  302. Water-Soluble Compounds from Lentinula edodes Influencing the HMG-CoA Reductase Activity and the Expression of Genes Involved in the Cholesterol Metabolism
  303. A minimal molecular toolkit for mineral deposition? Biochemistry and proteomics of the test matrix of adult specimens of the sea urchin Paracentrotus lividus
  304. New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?
  305. Plasma Cholesterol-Lowering Activity of Lard Functionalized with Mushroom Extracts Is Independent of Niemann–Pick C1-like 1 Protein and ABC Sterol Transporter Gene Expression in Hypercholesterolemic Mice
  306. Teriparatide for osteoporosis: importance of the full course
  307. Prospects for Increasing Sugarcane and Bioethanol Production on Existing Crop Area in Brazil
  308. Long-Term Predictors of Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Undergoing Electrical Cardioversion
  309. Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?
  310. Assessment of bleeding risk in acute ill medical patients. An essential part of venous thromboembolism prevention
  311. Current Antiarrhythmic Therapy for Nonvalvular Atrial Fibrillation in Spain. Data From the FANTASIIA Registry
  312. Clinical implications of nonsarcomeric gene polymorphisms in hypertrophic cardiomyopathy
  313. The SAMe-TT2R2score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation
  314. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
  315. Nanoscale assembly processes revealed in the nacroprismatic transition zone of Pinna nobilis mollusc shells
  316. Von Willebrand factor is associated with atrial fibrillation development in ischaemic patients after cardiac surgery
  317. The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective ‘Real-world’ Inception Cohort Study
  318. On the benefits of using HD-sEMG technique for estimating muscle force
  319. Clinical development of rivaroxaban: emerging new clinical evidences?
  320. Trastornos del desarrollo en niños y adolescentes de la región de Los Ríos, Valdivia, Chile, 2006-2008
  321. Friction coefficient analysis during high-heeled gait
  322. 3D location deduced by inertial measurement units: a challenging problem
  323. Proposition, identification, and experimental evaluation of an inverse dynamic neuromusculoskeletal model for the human finger
  324. Motion capture for functional analysis of new biomaterials in a small animal model
  325. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation
  326. sST2 levels are associated with all‐cause mortality in anticoagulated patients with atrial fibrillation
  327. Trichoderma saturnisporum, a new biological control agent
  328. Novel biomarkers in cardiology: MicroRNAs in atrial fibrillation
  329. The importance of excellence in the quality of anticoagulation control whilst taking vitamin K antagonists
  330. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Soc...
  331. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Socie...
  332. Probing deformed commutators with macroscopic harmonic oscillators
  333. De novo mutations in PLXND1 and REV3L cause Möbius syndrome
  334. Simulating tropical forage growth and biomass accumulation: an overview of model development and application
  335. Importance of Sudden Cardiac Death Risk Stratification in Hypertrophic Cardiomyopathy
  336. Satisfaction With Medical Care in Patients With Atrial Fibrillation Treated With Vitamin K Antagonists Versus New Oral Anticoagulants
  337. Comparison of Estimated Glomerular Filtration Rate Equations for Dosing New Oral Anticoagulants in Patients With Atrial Fibrillation
  338. Quality of Anticoagulation With Vitamin K Antagonists
  339. Modulation of cholesterol-related gene expression by ergosterol and ergosterol-enriched extracts obtained from Agaricus bisporus
  340. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
  341. CALU polymorphism A29809G affects calumenin availability involving vascular calcification
  342. Ultrastructure of the Interlamellar Membranes of the Nacre of the Bivalve Pteria hirundo, Determined by Immunolabelling
  343. Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry p...
  344. Spine and test skeletal matrices of the Mediterranean sea urchinArbacia lixula- a comparative characterization of their sugar signature
  345. Major bleeding risk prediction using Chronic Kidney Disease Epidemiology Collaboration and Modification of Diet in Renal Disease equations in acute coronary syndrome
  346. Update on Ischemic Heart Disease and Intensive Cardiac Care
  347. The test skeletal matrix of the black sea urchin Arbacia lixula
  348. Predictive ability of heel quantitative ultrasound for incident fractures: an individual-level meta-analysis
  349. Dysphagia Diagnosed by Fiberoptic Endoscopy Is Common and Transient in Critical Illness Polyneuropathy
  350. Lactational exposure to low levels of the six indicator non-dioxin-like polychlorinated biphenyls induces DNA damage and repression of neuronal activity, in juvenile male mice
  351. TWEAK and NT-proBNP levels predict exercise capacity in hypertrophic cardiomyopathy
  352. Remarkable Proanthocyanidin Adsorption Properties of Monastrell Pomace Cell Wall Material Highlight Its Potential Use as an Alternative Fining Agent in Red Wine Production
  353. Involvement of the −420C>G RETN polymorphism in myocardial fibrosis in patients with hypertrophic cardiomyopathy
  354. Effect of Selenium-Enriched Agaricus bisporus (Higher Basidiomycetes) Extracts, Obtained by Pressurized Water Extraction, on the Expression of Cholesterol Homeostasis Related Genes by Low-Density Array
  355. The search for optimal anticoagulation therapy in ACS: The gap between clinical trials and current clinical guidelines
  356. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists
  357. Comments on the 2014 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism
  358. Oral Anticoagulation in Japanese Patients With Atrial Fibrillation
  359. Effects of Body Mass Index on the Lipid Profile and Biomarkers of Inflammation and a Fibrinolytic and Prothrombotic State
  360. Lone Atrial Fibrillation- A Diagnosis of Exclusion
  361. GDF-15 and risk stratification in atrial fibrillation
  362. Red Cell Distribution Width and Coronary Artery Disease. Response
  363. SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation
  364. Reactivity of pure and commercial grape skin tannins with cell wall material
  365. Red Cell Distribution Width and Additive Risk Prediction for Major Bleeding in Non–ST-segment Elevation Acute Coronary Syndrome
  366. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group ...
  367. Dynamic Prognostic Stratification in ST–elevation Myocardial Infarction. Response
  368. Methods of kidney function assessment in non-valvular atrial fibrillation in the era of new oral anticoagulants
  369. Recanalization and Mortality Rates of Thrombectomy With Stent-Retrievers in Octogenarian Patients with Acute Ischemic Stroke
  370. C0487: NT-proBNP Provided Complementary Prognostic Information to an Established Clinical Risk Score (CHA2DS2-VASc) for the Prediction of Stroke/Systemic Embolism
  371. Use of Antithrombotic Therapy in Patients With Atrial Fibrillation in Primary Care. Importance of INR Control
  372. Small-size platelet microparticles trigger platelet and monocyte functionality and modulate thrombogenesis via P-selectin
  373. Prognostic value of two polymorphisms in non-sarcomeric genes for the development of atrial fibrillation in patients with hypertrophic cardiomyopathy
  374. Usefulness of N-Terminal Pro–B-Type Natriuretic Peptide Levels for Stroke Risk Prediction in Anticoagulated Patients With Atrial Fibrillation
  375. Update on Ischemic Heart Disease and Critical Care Cardiology
  376. Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation
  377. The optimal management of patients on oral anticoagulation undergoing coronary artery stenting
  378. Interleukin-6 as a predictor of cardiovascular events in troponin-negative non-ST elevation acute coronary syndrome patients
  379. Biomarkers in atrial fibrillation: an overview
  380. The HAS-BLED Score Has Better Prediction Accuracy for Major Bleeding Than CHADS2 or CHA2DS2-VASc Scores in Anticoagulated Patients With Atrial Fibrillation
  381. β-Trace Protein and Prognosis in Patients With Atrial Fibrillation Receiving Anticoagulation Treatment
  382. Manifestaciones neurológicas de los mixomas cardiacos. Experiencia en un centro de referencia
  383. High-sensitivity troponin T as a biomarker for the development of atrial fibrillation after cardiac surgery
  384. Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard?
  385. Role of microRNAs in cardiac remodelling: New insights and future perspectives
  386. N-terminal Pro-brain Natriuretic Peptide and High-sensitivity Troponin in the Evaluation of Acute Chest Pain of Uncertain Etiology. A PITAGORAS Substudy
  387. The complex role of bone turnover biomarkers in cardiovascular diseases
  388. Identification and confirmation of haptoglobin as a potential serum biomarker in hypertrophic cardiomyopathy using proteomic approaches
  389. Letter by Marín et al Regarding Article, “Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and Coronary Intervention: A Nationwide Cohort Study”
  390. Renal Impairment in a “Real-Life” Cohort of Anticoagulated Patients With Atrial Fibrillation (Implications for Thromboembolism and Bleeding)
  391. Small-size circulating microparticles in acute coronary syndromes: Relevance to fibrinolytic status, reparative markers and outcomes
  392. Interleukin-6 and High-sensitivity C-reactive Protein for the Prediction of Outcomes in Non-ST-segment Elevation Acute Coronary Syndromes
  393. Eco-Doppler de ejercicio en pacientes con miocardiopatía hipertrófica. Factores determinantes de la limitación funcional
  394.  -Trace Protein: From GFR Marker to Cardiovascular Risk Predictor
  395. Beta-Trace Protein and Cystatin C as Predictors of Major Bleeding in Non-ST-Segment Elevation Acute Coronary Syndrome
  396. Antithrombotic therapy in atrial fibrillation and stent implantation: treatment or threats by the use of triple or dual antithrombotic therapy
  397. Tratamiento antitrombótico y tipo de stent en pacientes con fibrilación auricular a los que se practica una intervención coronaria percutánea
  398. Antithrombotic therapy and bleeding risk in atrial fibrillation. Fewer unanswered questions
  399. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation
  400. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?
  401. Oral anticoagulation for heart failure in sinus rhythm: from evidence to clinical recommendations, or not?
  402. Predictive Value of the HAS-BLED and ATRIA Bleeding Scores for the Risk of Serious Bleeding in a “Real-World” Population With Atrial Fibrillation Receiving Anticoagulant Therapy
  403. The prognostic role of the adiponectin levels in atrial fibrillation
  404. Atherosclerosis and thromboembolic risk in atrial fibrillation: Focus on peripheral vascular disease
  405. Prior aspirin therapy and cardiovascular implantable electronic device infections
  406. High sensitivity cardiac troponin T and interleukin‐6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation: a reply to a rebuttal
  407. Usefulness of β-Trace Protein and Cystatin C for the Prediction of Mortality in Non ST Segment Elevation Acute Coronary Syndromes
  408. Comparative Determination and Monitoring of Biomarkers of Necrosis and Myocardial Remodeling between Radiofrequency Ablation and Cryoablation
  409. Ankle brachial index as an independent predictor of mortality in anticoagulated atrial fibrillation
  410. Pre and Post-Operative Treatments for Prevention of Atrial Fibrillation after Cardiac Surgery
  411. Oral anticoagulation improves the prognosis of octogenarian patients with atrial fibrillation undergoing percutaneous coronary intervention and stenting
  412. Usefulness of high-sensitivity troponin T for the evaluation of patients with acute chest pain and no or minimal myocardial damage
  413. High sensitivity cardiac troponin T and interleukin‐6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation
  414. Should We Recommend Oral Anticoagulation Therapy in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting With a High HAS-BLED Bleeding Risk Score?
  415. Subclinical atherosclerotic endothelial damage as predictor for bleeding in anticoagulated atrial fibrillation patients
  416. Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis
  417. Predictive Value of the CHA2DS2-VASc Score in Atrial Fibrillation Patients at High Risk for Stroke Despite Oral Anticoagulation
  418. Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable?
  419. Relation of the HAS-BLED Bleeding Risk Score to Major Bleeding, Cardiovascular Events, and Mortality in Anticoagulated Patients With Atrial Fibrillation
  420. Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy
  421. Influence of CYP2C19 Polymorphisms in Platelet Reactivity and Prognosis in an Unselected Population of Non ST Elevation Acute Coronary Syndrome
  422. Pharmacological Modulation of Microparticle Release: New Strategies for the Management of Atherothrombotic Vascular Disorders
  423. CardioPulse Articles
  424. New Perspectives in Antiplatelet Therapy
  425. Edoxaban in Japanese Patients With Nonvalvular Atrial Fibrillation
  426. High-Sensitivity Troponin T and Copeptin in Non-ST Acute Coronary Syndromes: Implications for Prognosis and Role of hsTnT and Copeptin in Non-STEACS
  427. Mild kidney disease as a risk factor for major bleeding in patients with atrial fibrillation undergoing percutaneous coronary stenting
  428. New Evidence, New Controversies: a Critical Review of the European Society of Cardiology 2010 Clinical Practice Guidelines on Atrial Fibrillation
  429. Oral anticoagulation in chronic kidney disease: A huge challenge
  430. Primary Prevention With Aspirin in Type 2 Diabetic Patients
  431. Pro: “Antidote for new anticoagulants” – Specific target of inhibition requires a specific target for neutralisation
  432. Stroke and Thromboembolism in Atrial Fibrillation
  433. The ATRIA Risk Scheme to Predict Warfarin-Associated Hemorrhage
  434. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm
  435. Is plasminogen activator inhibitor-1 (PAI-1) a surrogate marker of vascular damage?
  436. A New Landscape for Stroke Prevention in Atrial Fibrillation
  437. Prevención de complicaciones hemorrágicas en el síndrome coronario agudo
  438. Influence of cardiac resynchronization therapy on indices of inflammation, the prothrombotic state and tissue remodeling in systolic heart failure: A pilot study
  439. The Improved but Unfinished Business of Stroke Risk Stratification in Atrial Fibrillation
  440. Prognostic Value of Mean Platelet Volume in Patients With Non-ST-Elevation Acute Coronary Syndrome
  441. An Insight of Novel Pharmacological Therapies in Hypertrophic Cardiomyopathy
  442. Circulating microparticles: new insights into the biochemical basis of microparticle release and activity
  443. Interactions Between Clopidogrel and Proton Pump Inhibitors: A Review of Evidence
  444. Plasma von Willebrand Factor Levels Are an Independent Risk Factor for Adverse Events Including Mortality and Major Bleeding in Anticoagulated Atrial Fibrillation Patients
  445. An Evaluation of the CHADS2 Stroke Risk Score in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Revascularization
  446. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis
  447. Impact of polymorphisms in the renin–angiotensin–aldosterone system on hypertrophic cardiomyopathy
  448. Peri-operative management of ophthalmic patients taking antithrombotic therapy
  449. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Similarities and dissimilarities between North America and Europe
  450. Bleeding risk assessment and management in atrial fibrillation patients
  451. Collagen peptides, interstitial remodelling and sudden cardiac death in hypertrophic cardiomyopathy
  452. Serum Levels of High-Sensitivity Troponin T: A Novel Marker for Cardiac Remodeling in Hypertrophic Cardiomyopathy
  453. Thrombogenesis in lone atrial fibrillation: a role for soluble P-selectin?
  454. The prognostic value of biomarkers after a premature myocardial infarction
  455. Rhythm control agents and adverse events in patients with atrial fibrillation
  456. Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk
  457. CALU A29809G polymorphism in coronary atherothrombosis: Implications for coronary calcification and prognosis
  458. Plasma levels of Von Willebrand factor are increased in patients with hypertrophic cardiomyopathy
  459. Enzyme Replacement Therapy in Fabry Disease: Influence on Cardiac Manifestations
  460. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed b...
  461. Hypouricemic effect of statins: Another pleiotropic benefit?
  462. Effects of atorvastatin 80 mg daily on indices of matrix remodelling in ‘high-risk’ patients with ischemic heart disease
  463. The additive value of biomarkers to clinical risk scores in acute coronary syndrome. Are biomarkers really ready for real world usage?
  464. Glycoprotein inhibitors in patients on chronic anticoagulation: Safe enough or too much risk?
  465. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting
  466. Synergism between factor XII –4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction
  467. Miocardiopatía hipertrófica. Estudio del gen de la troponina T en 127 familias españolas
  468. ¿Existe un efecto beneficioso a largo plazo con el tratamiento con marcapasos de la miocardiopatía hipertrófica obstructiva severa?
  469. Biomarcadores en la estratificación del riesgo del síndrome coronario agudo sin elevación del segmento ST: ¿hay algo más después de la troponina?
  470. Left atrial remodelling in hypertrophic cardiomyopathy: relation with exercise capacity and biochemical markers of tissue strain and remodelling
  471. Pharmacogenetics in Cardiovascular Antithrombotic Therapy
  472. Premature coronary artery disease in young (age < 45) subjects: Interactions of lipid profile, thrombophilic and haemostatic markers
  473. Implications of Pharmacogenetics for Oral Anticoagulants Metabolism
  474. Antithrombotic therapy use for patients with atrial fibrillation undergoing percutaneous coronary intervention: new data in an area of limited evidence
  475. “Antithrombotic therapy after coronary stenting in patients with indication for oral anticoagulation”
  476. Does the Holy Grail escape us again?
  477. Impact of Chronic Kidney Disease on Major Bleeding Complications and Mortality in Patients With Indication for Oral Anticoagulation Undergoing Coronary Stenting
  478. Dispersión del intervalo QT y miocardio viable
  479. Influence of electrical cardioversion on inflammation and indexes of structural remodeling, in persistent atrial fibrillation
  480. Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis
  481. Is thrombogenesis related to residual platelet function in ischaemic heart disease?
  482. Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation
  483. Endothelial protein C receptor polymorphisms and risk of myocardial infarction
  484. Increased Major Bleeding Complications Related to Triple Antithrombotic Therapy Usage in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Artery Stenting
  485. Hypertension, aortic sclerosis and the prothrombotic state: understanding the complex interaction
  486. The impact of statin use on atrial fibrillation
  487. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy
  488. Antithrombotic Therapy Use After Percutaneous Coronary Intervention and Stent Implantation in Patients Taking Chronic Oral Anticoagulation
  489. Variables Associated With Contrast-Enhanced Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy: Clinical Implications
  490. Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis
  491. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms
  492. Reply
  493. Premature myocardial infarction: Clinical profile and angiographic findings
  494. Unable to speak—because of a drip
  495. Anaemia as predictor of gastrointestinal bleeding in atrial fibrillation patients undergoing percutaneous coronary artery stenting
  496. Mortality in patients with atrial fibrillation: improving or not?
  497. Short- and long-term effects of growth hormone on the heart
  498. Letter by Roldán et al Regarding Article, “Plasminogen Activator Inhibitor-1 as a Predictor of Postoperative Atrial Fibrillation After Cardiopulmonary Bypass”
  499. Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation
  500. Gadolinium-Enhanced Cardiovascular Magnetic Resonance and Exercise Capacity in Hypertrophic Cardiomyopathy
  501. Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'
  502. Factor VII –323 decanucleotide D/I polymorphism in atrial fibrillation: Implications for the prothrombotic state and stroke risk
  503. Is There a Role for Levosimendan in Hospital Emergency Departments?
  504. TUBB1 Q43P polymorphism does not protect against acute coronary syndrome and premature myocardial infarction
  505. Prevalence of Fabry Disease in a Cohort of 508 Unrelated Patients With Hypertrophic Cardiomyopathy
  506. A multimarker risk stratification approach to non‐ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro‐BNP and fibrin D‐dimer levels
  507. Plasma angiogenin levels in acute coronary syndromes: implications for prognosis
  508. Respuesta
  509. Matrix metalloproteinase‐1 and its inhibitor, TIMP‐1, in systolic heart failure: relation to functional data and prognosis
  510. Coronary aneurysms after drug-eluting stents implantation
  511. Pharmacologic Therapy in Growth Hormone Disorders and the Heart
  512. Prognostic value of annexin A5 −1 C/T polymorphism in a long term follow‐up after premature myocardial infarction
  513. Common Carotid Artery Intima-Media Thickness and Intracranial Pulsatility Index in Non-ST-Elevation Acute Coronary Syndromes
  514. Effect of Statins on Preventing Recurrence of Atrial Fibrillation After Electrical Cardioversion
  515. Antiplatelet versus anticoagulant therapies in advanced age: An unfinished task
  516. Atrial stunning as predictor of early relapse into atrial fibrillation after cardioversion
  517. Is an advanced age an additive risk factor to the prothrombotic or hypercoagulable state in atrial fibrillation?
  518. Desfibrilador automático en la miocardiopatía hipertrófica. Experiencia de 3 centros
  519. Does smoking status influence the effect of physical exercise on fibrinolytic function in healthy volunteers?
  520. Growth Hormone Therapy and the Heart
  521. Fluctuations in Coagulation Activity Among Patients with Atrial Fibrillation who are Stably Anticoagulated
  522. Statins and Postoperative Risk of Atrial Fibrillation Following Coronary Artery Bypass Grafting
  523. Cardiac tamponade following pacemaker implantation
  524. Efecto de dosis máximas de atorvastatina en la inflamación, la trombogénesis y la función fibrinolítica en pacientes con cardiopatía isquémica de alto riesgo
  525. Polimorfismos en la región Kozak del FXII y su relación con el infarto agudo de miocardio prematuro
  526. Are there ethnic differences in the circadian variation in onset of acute myocardial infarction?
  527. Relation of interleukin-6 levels and prothrombin fragment 1+2 to a point-based score for stroke risk in atrial fibrillation
  528. Plasma Concentration of Big Endothelin-1 and Its Relation With Plasma NT-proBNP and Ventricular Function in Heart Failure Patients
  529. Influence of smoking habit on cardiac functional capacity and diastolic function in healthy people
  530. Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation
  531. A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction
  532. Synergistic association between hypercholesterolemia and the C46T factor XII polymorphism for developing premature myocardial infarction
  533. Effect of factor VII −323 Del/Ins polymorphism on the daily variability of factor VIIc and INR in steady anticoagulated patients with acenocoumarol
  534. Can We Expect Polymorphisms to Answer our Questions?
  535. Short alleles of P-selectin glycoprotein ligand-1 protect against premature myocardial infarction
  536. Genetic Polymorphisms and Thromoembolic Risk in Atrial Fibrillation
  537. Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation
  538. Are we content with lowering blood pressure alone, or should we be asking something more from the antihypertensive drugs we use?: effects of antihypertensive agents on fibrinolytic function
  539. NT-proBNP Levels and Hypertension. Their Importance in the Diagnosis of Heart Failure
  540. Effects of Pretreatment with Intravenous Flecainide on Efficacy of External Cardioversion of Persistent Atrial Fibrillation
  541. Hypoxemia and Stroke in a Patient With a Pacemaker
  542. Growth Hormone Therapy , Is it Always Good for the Heart?
  543. Matrix metalloproteinases in atrial fibrillation
  544. Fractional shortening-velocity ratio for assessment of aortic stenosis severity in patients with systolic dysfunction
  545. NT-proBNP y desplazamiento del plano auriculoventricular. Relación e implicaciones diagnósticas
  546. Heart valve disease in acromegaly
  547. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation
  548. Angiogénesis y estatinas, ¿a mayor dosis, mayor beneficio?
  549. Is Thrombogenesis in Atrial Fibrillation Related to Matrix Metalloproteinase-1 and Its Inhibitor, TIMP-1?
  550. Role of factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction
  551. Fibrinolytic function and atrial fibrillation
  552. 1438 Hypercoagulable state detected in atrial fibrillation patients is unrelated to clinical predictors to embolism
  553. 277 Is there quality of life improvement after upgrading to dual-chamber pacing in patients with VVI pacemakers?
  554. Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer levels in acute-onset nonrheumatic atrial fibrillation
  555. Valor pronóstico de los niveles séricos del factor de necrosis tumoral alfa en pacientes con insuficiencia cardíaca
  556. Soluble E-selectin in cardiovascular disease and its risk factors
  557. Diurnal variation of international normalised ratio in patients under oral anticoagulation
  558. Cardiac involvement in Fabry disease
  559. A common polymorphism in the annexin V Kozak sequence (−1C>T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients
  560. Prothrombin fragment F1+2 and von Willebrand factor levels and left ventricular systolic function. Peripheral versus intracardiac blood samples
  561. Do protein Z levels influence the prothrombotic state in atrial fibrillation?
  562. Low QRS voltage in cardiac tamponade: a study of 70 cases
  563. The role of tissue plasminogen activator on the progression of the coronary disease
  564. Anexina V en pacientes supervivientes de un infarto de miocardio prematuro
  565. Diurnal Variation in the Intensity of Anticoagulation in Atrial Fibrillation
  566. Effect of Factor XIII VAL34LEU Polymorphism on Thrombolytic Therapy in Premature Myocardial Infarction
  567. Polimorfismo Val34Leu del factor XIII e infarto de miocardio prematuro
  568. Infrautilización del tratamiento anticoagulante en pacientes con fibrilación auricular
  569. Tissue factor/tissue factor pathway inhibitor system and long-term prognosis after acute myocardial infarction
  570. Anticoagulant Therapy Modifies Fibrinolytic Dysfunction in Chronic Atrial Fibrillation
  571. Prothrombotic state and elevated levels of plasminogen activator inhibitor-1 in mitral stenosis with and without atrial fibrillation
  572. Acute cardiac rupture complicating pre-discharge exercise testing. A case report with complete echocardiographic follow-up
  573. Hypofibrinolysis in atrial fibrillation
  574. Antiplatelet Therapy in Stroke Prevention